ADMA Biologics, Inc. (ADMA)
9.545
-0.30
(-3.00%)
USD |
NASDAQ |
Aug 24, 16:00
9.545
0.00 (0.00%)
After-Hours: 20:00
ADMA Biologics Net Income (Quarterly) : 37.82M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 37.82M |
| March 31, 2026 | 45.33M |
| December 31, 2025 | 49.38M |
| September 30, 2025 | 36.43M |
| June 30, 2025 | 34.22M |
| March 31, 2025 | 26.90M |
| December 31, 2024 | 111.90M |
| September 30, 2024 | 35.91M |
| June 30, 2024 | 32.06M |
| March 31, 2024 | 17.81M |
| December 31, 2023 | -17.64M |
| September 30, 2023 | 2.565M |
| June 30, 2023 | -6.371M |
| March 31, 2023 | -6.789M |
| December 31, 2022 | -12.23M |
| September 30, 2022 | -14.90M |
| June 30, 2022 | -13.76M |
| March 31, 2022 | -25.01M |
| December 31, 2021 | -16.65M |
| September 30, 2021 | -17.71M |
| June 30, 2021 | -18.91M |
| March 31, 2021 | -18.38M |
| December 31, 2020 | -19.41M |
| September 30, 2020 | -16.92M |
| June 30, 2020 | -20.18M |
| Date | Value |
|---|---|
| March 31, 2020 | -19.25M |
| December 31, 2019 | -10.56M |
| September 30, 2019 | -11.44M |
| June 30, 2019 | -13.21M |
| March 31, 2019 | -13.07M |
| December 31, 2018 | -18.04M |
| September 30, 2018 | -15.14M |
| June 30, 2018 | -14.75M |
| March 31, 2018 | -17.82M |
| December 31, 2017 | -12.98M |
| September 30, 2017 | -15.20M |
| June 30, 2017 | -9.036M |
| March 31, 2017 | -6.537M |
| December 31, 2016 | -4.559M |
| September 30, 2016 | -4.331M |
| June 30, 2016 | -6.012M |
| March 31, 2016 | -4.612M |
| December 31, 2015 | -4.583M |
| September 30, 2015 | -5.102M |
| June 30, 2015 | -4.679M |
| March 31, 2015 | -3.606M |
| December 31, 2014 | -3.563M |
| September 30, 2014 | -3.385M |
| June 30, 2014 | -3.961M |
| March 31, 2014 | -5.904M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Erasca, Inc. | -44.08M |
| Krystal Biotech, Inc. | 54.77M |
| Vericel Corp. | 2.206M |
| Emergent BioSolutions, Inc. | -180.20M |
| Exelixis, Inc. | 212.05M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 124.40M |
| Total Expenses (Quarterly) | 86.57M |
| EPS Diluted (Quarterly) | 0.1642 |
| Enterprise Value | 2.285B |
| Gross Profit Margin (Quarterly) | 69.31% |
| Profit Margin (Quarterly) | 30.40% |
| Earnings Yield | 7.38% |
| Operating Earnings Yield | 9.46% |
| Normalized Earnings Yield | 7.446 |